Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 3/3010% below fair value
$7.62−0.36 (-4.51%)
Close on Nov 20, 2026Market cap $221.94MP/E –Yield –
Enanta Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Enanta Pharmaceuticals
Enanta Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?